Incidence of SARS-CoV-2 Infection, Emergency Department Visits, and Hospitalizations Because of COVID-19 Among Persons Aged ≥12 Years, by COVID-19 Vaccination Status — Oregon and Washington, July 4–September 25, 2021

Naleway, Allison L.; Groom, Holly; Crawford, Phil; Salas, S Bianca; Henninger, Michelle; Donald, Judy; Smith, Norman J.; Thompson, Mark G.; Blanton, Lenee; Bozio, Catherine H; Azziz‐Baumgartner, Eduardo

doi:10.15585/mmwr.mm7046a4

Cited by 36 publications

(30 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As of January 17, 2022, 326 million cases and 5.5 million deaths worldwide have been reported [ 2 ]. Vaccine breakthrough COVID-19 constitutes a small percentage (~ 1.5%) of all fully vaccinated cases [ 3 , 4 ] but is expected to rise as COVID-19 vaccine effectiveness is waning over time and new SARS-CoV-2 variants emerge.…”

Section: Introductionmentioning

confidence: 99%

COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab

et al. 2022

View full text Add to dashboard Cite

Introduction The SARS-CoV-2 pandemic necessitated better understanding of the impact of disease-modifying therapies on COVID-19 outcomes and vaccination. We report characteristics of COVID-19 cases and vaccination status in ofatumumab-treated relapsing multiple sclerosis (RMS) patients. Methods COVID-19 data analyzed were from the ongoing, open-label, long-term extension phase 3b ALITHIOS study from December 2019 (pandemic start) and post-marketing cases from August 2020 (ofatumumab first approval) up to 25 September 2021. COVID-19 cases, severity, seriousness, outcomes, vaccination status, and breakthrough infection were evaluated. Results As of 25 September 2021, 245 of 1703 patients (14.3%) enrolled in ALITHIOS receiving ofatumumab (median exposure: 2.45 years) reported COVID-19 (confirmed: 210; suspected: 35). Most COVID-19 was of mild (44.1%) or moderate (46.5%) severity, but 9% had severe/life-threatening COVID-19. There were 24 serious cases (9.8%) with 23 patients were hospitalized; 22 recovered and 2 died. At study cut-off, 241 patients (98.4%) had recovered or were recovering or had recovered with sequelae and 2 (0.8%) had not recovered. Ofatumumab was temporarily interrupted in 39 (15.9%) patients. Before COVID-19 onset, IgG levels were within the normal range in all COVID-19–affected patients, while IgM was < 0.4 g/l in 23 (9.4%) patients. No patient had a reinfection. Overall, 559 patients were vaccinated (full, 476; partial, 74; unspecified, 9). Breakthrough infection was reported in 1.5% (7/476) patients, and 11 reported COVID-19 after partial vaccination. As of 25 September 2021, the Novartis Safety Database (~ 4713 patient-treatment years) recorded 90 confirmed COVID-19 cases receiving ofatumumab. Most cases were non-serious ( n = 80), and ten were serious (1 medically significant, 9 hospitalized, 0 deaths). Among 36 of 90 cases with outcomes reported, 30 recovered and 6 did not recover. Conclusion COVID-19 in RMS patients on ofatumumab was primarily of mild/moderate severity and non-serious in these observational data. Most recovered from COVID-19 without treatment interruption. Two people died with COVID-19. Breakthrough COVID-19 despite being fully/partially vaccinated was uncommon. Supplementary Information The online version contains supplementary material available at 10.1007/s40120-022-00341-z.

show abstract

Section: Introductionmentioning

confidence: 99%

COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab

et al. 2022

View full text Add to dashboard Cite

show abstract

“…This finding is comparable to other studies conducted when the Delta variant was widespread. 1,3 In this cohort, unvaccinated students had eight times higher incidence of documented infection and less than 1% of vaccinated students reported an infection. As one primary infection can trigger a substantial number of quarantines, these findings indicate that vaccination may play…”

Section: Discussionmentioning

confidence: 72%

“…Coronavirus disease 2019 (COVID-19), school closures, and quarantines have had substantial impacts on students' health and education. 1,2,3 Clinical trials have shown severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines to be safe and efficacious for adults, adolescents, and young children. 4 However, in some areas, vaccine uptake has been low among children and adolescents, especially compared to uptake in adults.…”

Section: Introductionmentioning

confidence: 99%

“…4 However, in some areas, vaccine uptake has been low among children and adolescents, especially compared to uptake in adults. 1 Additionally, real-world vaccine effectiveness data among adolescents and implications for in-person education are lacking. We investigated the impact of COVID-19 vaccination on SARS-CoV-2 incidence and within-school transmission in a cohort of 6 th -12 th grade students.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 Incidence Among Sixth Through Twelfth Grade Students by Vaccination Status

et al. 2022

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), school closures, and quarantines have had substantial impacts on students’ health and education.1,2,3 Clinical trials have shown severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines to be safe and efficacious for adults, adolescents, and young children.4 However, in some areas, vaccine uptake has been low among children and adolescents, especially compared to uptake in adults.1 Additionally, real-world vaccine effectiveness data among adolescents and implications for in-person education are lacking. We investigated the impact of COVID-19 vaccination on SARS-CoV-2 incidence and within-school transmission in a cohort of 6th-12th grade students.

show abstract

“…Further US-based studies confirmed the important role of obesity and a past medical history of diabetes as significantly more prevalent in hospitalized children, while the history of asthma or lower socioeconomic status did not reach statistical significance [ 66 ]. Among children aged ≥12 years in Oregon and Washington states in the USA, the incidence of SARS-CoV-2 infection in the July-September 2021 period was 30.1 per 1000 unvaccinated persons and 8.7 per 1000 vaccinated [ 67 ].…”

Section: Early Research On the Symptoms And Spreading Of The Sars-cov-2 Among Children And Young Peoplementioning

confidence: 99%

The COVID-19 pandemic in children and young people during 2020-2021: Learning about clinical presentation, patterns of spread, viral load, diagnosis and treatment

et al. 2021

View full text Add to dashboard Cite

Incidence of SARS-CoV-2 Infection, Emergency Department Visits, and Hospitalizations Because of COVID-19 Among Persons Aged ≥12 Years, by COVID-19 Vaccination Status — Oregon and Washington, July 4–September 25, 2021

Cited by 36 publications

References 3 publications

COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab

COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab

COVID-19 Incidence Among Sixth Through Twelfth Grade Students by Vaccination Status

The COVID-19 pandemic in children and young people during 2020-2021: Learning about clinical presentation, patterns of spread, viral load, diagnosis and treatment

Contact Info

Product

Resources

About